Oligo(carbamoylated guanidine) compounds disrupt mycobacterial membrane potential
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current TB treatment regimens are lengthy and ineffective against multidrug-resistant Mycobacterium tuberculosis due to the difficulty in targeting dormant or slow-growing bacterial cells, as most anti-TB drugs were developed to act on replicating cells, and existing antimicrobial peptides lack specificity and stability to efficiently target mycobacterial membranes.
Innovation Solution
Development of oligo(carbamoylated guanidine) compounds with a neutral backbone and cationic ends, which selectively disrupt the bacterial membrane potential, dissipate the proton motive force, and deplete ATP production, thereby targeting both replicating and dormant mycobacteria with high antimycobacterial selectivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional anti-TB drugs are used to treat Mycobacterium tuberculosis, then replicating cells can be targeted, but dormant or slow-growing cells cannot be effectively killed, leading to lengthy treatment regimens
Solution Approach 1:
The patent changes the mechanism of action parameter from replication-dependent to membrane potential-dependent. The compounds oligo(carbamoylated guanidine) with structure formula (I) act on the membrane potential of bacteria, which is maintained in both replicating and dormant cells, thereby eliminating the time loss associated with treating dormant cells
Solution Approach 2:
The patent replaces the biochemical mechanism (targeting replication processes) with a biophysical mechanism (targeting membrane potential). The compounds disrupt the electrochemical gradient across the bacterial membrane through their cationic structure, which interacts with the negative charge on the membrane surface, thereby killing both replicating and dormant cells regardless of their metabolic state
2Reliability
If antimicrobial peptides are used to target bacterial membranes, then bactericidal activity is achieved, but specificity to mycobacteria is insufficient due to the rigid and waxy envelope structure
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features optimized for mycobacterial membranes. The oligo(carbamoylated guanidine) structure with formula (I) contains cationic guanidine groups that interact with the specific negative charge distribution on mycobacterial membranes, providing both activity and selectivity
Solution Approach 2:
The patent creates a composite molecular structure combining hydrophobic regions (for membrane insertion) and cationic guanidine regions (for electrostatic interaction with membrane surface). This composite structure enables the compound to effectively penetrate and disrupt the rigid mycobacterial envelope while maintaining selectivity
3Object-affected harmful factors
If positively charged AMPs are used to interact with bacterial membranes, then membrane disruption is achieved, but efficiency is reduced against mycobacteria due to the less negatively charged envelope
Solution Approach 1:
The patent changes the charge parameter from simple positive charge to multiple cationic guanidine groups per molecule. The oligo(carbamoylated guanidine) structure contains multiple positive charges that can collectively interact with the less negatively charged mycobacterial membrane, compensating for the reduced electrostatic attraction and maintaining high efficacy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The oligo(carbamoylated guanidine) compounds exhibit fast and selective bactericidal effects against Mycobacterium tuberculosis, reducing treatment duration and overcoming drug resistance by disrupting membrane energetics, while maintaining low toxicity to host cells.
Implementation Method 1
dissipate the proton motive force, and deplete ATP production
Implementation Method 2
selectively disrupt the bacterial membrane potential
Data Source
AI summary
The subject invention provides oligo(carbamoylated guanidine)s (OCGs) having fast and selective mycobactericidal effects via disruption of the mycobacterial membrane potential. OCGs also potentiates bedaquiline, an oxidative phosphorylation-targeting anti-TB drug. The combination of OCG and anti-TB drug can be used as an effective therapy for treating tuberculosis.